JCN Newswire
Read More

Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region

ruth
4 minutes

TOKYO, Jan 26, 2023 - (JCN Newswire via SEAPRWire.com) - Nippon Steel Corporation, Mitsubishi Corporation and ExxonMobil Asia Pacific Pte. Ltd. have signed a Memorandum of Understanding to jointly study carbon capture and storage (CCS) and the establishment of potential CCS value chains in the Asia Pacific regions on January 25, 2023. Based on the Memorandum, the three companies will conduct research on the capture of CO2 emissions from Nippon Steel's domestic steelworks and evaluate the necessary infrastructure development required, with a view to establishing CCS value chains in the Asia-Pacific region. It would also include a detailed evaluation of Asia Pacific storage opportunities, including in Malaysia, Indonesia and Australia. Mitsubishi Corporation plans to evaluate the overseas CO2 transportation and the development of CCS value chain. This is the first study to develop value chains for carbon capture in Japan with the aim to store elsewhere overseas in the region. Nippon Steel set forth the "Nippon Steel Carbon Neutral Vision 2050" in its medium- to long-term management plan announced in March 2021 and positioned CCS as one of the key technologies to realize this vision. ...

JCN Newswire
Read More

Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis

ruth
3 minutes

TOKYO, Nov 16, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis. nippon medac obtained the manufacturing and marketing approval of Japan's first self-administrable subcutaneous injection formulation of MTX, a first line option for the treatment of rheumatoid arthritis, on September 26, 2022. The product is published to Japan's National Health Insurance Drug Price List, today.The approval of Metoject in Japan is based on the results of a Phase III clinical trial (MC-MTX.17/RA) conducted in Japan by nippon medac to compare the efficacy and safety of Metoject with that of oral MTX, which consisted of a double-blind phase and an extension phase. Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for produ...

SeaPRwire
Read More

Singapore paint billionaire gets windfall as dream deal comes true

elean
3 minutes

SINGAPORE (BLOOMBERG) - Almost a decade ago, the son of Singapore paint tycoon Goh Cheng Liang set his sights on gaining control of Japan's biggest paint maker. He finally succeeded, and that's been a boon for the family's wealth. Their Wuthelam Holdings took a majority stake in Nippon Paint Holdings in a US$12 billion (S$16 billion) deal that was completed last month, according to filings this week. That's boosted their fortune to US$24 billion from about US$16 billion before the alliance was announced, according to the Bloomberg Billionaires Index. For years, Wuthelam and Nippon Paint operated a business with joint ventures in countries including China, India and Malaysia. In August, Nippon Paint struck an agreement that allowed them to buy out the joint venture and take over Wuthelam's wholly owned Indonesia business. In turn, the Gohs' increased their stake in Nippon Paint to about 58 per cent. "The growth will continue," said Bloomberg Intelligence analyst Horace Chan, who estimates the alliance could lift Nippon Paint's net income by about 64 per cent this year. "It will help the company in terms of simplifying the corporate structure, which will allow more efficient allocati...